Delfini et al report additional indirect evidence that cytogenetic remissions of chronic myloid leukemia (CML) in response to interferon-a are associated with changes in immunoregulatory cell populations. The finding of concomitant upregulation of costimulatory molecules on antigen-presenting cells and expansion of CD8 cell populations is consistent with the hypothesis that interferon-a can induce clonal antigen-presenting cells to effectively present CML antigens, resulting in expansion of antileukemic cytotoxic T cells. In addition, cytogenetic remissions to interferon-a in CML have been shown to be associated with in vivo expansion of cytotoxic T lymphocytes specific for the myeloid-specific antigen proteinase 3.
A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis Leukemia (2003 Leukemia ( ) 17, 985-986. doi:10.1038 TO THE EDITOR Multiple sclerosis (MS) is an autoimmune disease characterised by a relapsing-remitting course or by a gradual decline of neurologic function caused by immune activity directed against central nervous system antigens. At present, an immunosuppressive or immunomodulatory therapy seems to be most promising.
1 Indeed, although MS has been considered for long time as an unmanageable disease, some drugs have recently shown activity in controlled studies and have been approved for therapeutic use. Among them mitoxantrone, an anthracenedione synthetic agent, has been licensed for use in secondary progressive and progressive relapsing MS, and there is consensus on the earlier use of active drugs before irreversible clinical disability has developed. 2 The mechanism of action of mitoxantrone in MS is poorly understood. Its common side effects include cardiac and hematological toxicity. A potentially fatal side effect is the development of acute myeloblastic leukemia/myelodysplastic syndrome (AML/MDS). In fact, like other topoisomerase-II (topo-II) inhibitors, mitoxantrone can induce DNA cleavage and chromosome aberrations, including sister chromatids exchanges, thus favouring the development of neoplastic clones.
3 The development of secondary leukemia in MS patients treated with chlorambucil, an alkylating agent with well-known leukemogenic potential, has been documented in the past. 4 Recently, two cases /die for 30 days consecutively). For the occurrence of leucocytosis, idarubicin was added on days 4 and 6 at the dose of 12 mg/m 2 /die. The treatment was well tolerated and on day +24, normal haematopoiesis started to restore. A marrow aspirate performed after complete haematological recovery showed morphological and cytogenetic complete remission, whereas molecular remission was achieved after the first of the three consolidation cycles with idarubicin and ATRA. However, PMLRARa positivity was detected 5 months after diagnosis, after the end of consolidation, while the patient was still in complete remission. The patient is currently alive and well on ATRA reinduction therapy. No effects on the course of MS were observed during leukemia treatment.
As for other topo-II inhibitors (eg anthracyclines and epipodophyllotoxins) the leukemogenic potential of mitoxantrone has been well established, particularly in breast cancer patients, in which the risk of developing secondary AML/MDS was 10-fold higher after mitoxantrone-based regimens.
7 However in most cases, patients had also received other cytostatic drugs, including alkylating agents, with or without radiotherapy. Typically the latency was short, with a median time of 13-36 months from the start of chemotherapy 8 and the onset of leukaemia was sudden.
Promyelocytic leukaemia (FAB M3), together with M4 and M5, was among the typical FAB subtypes of AML/MDS induced by topo-II inhibitors. Balanced chromosomal translocations like t(15;17) were also characteristic, including t(8;21), involvement of 11q23, and inv(16).
3 In a recent international workshop, 41 cases of 'secondary' APL could be collected and analysed.
8 Topo-II inhibitors had been used in half of the cases and mitoxantrone in 35% of them. Of note there were no cases treated with topo-II inhibitors alone and only one patient had been treated for a nonmalignant disease. of b-IFN. On the other hand, although a de novo leukaemia cannot be completely excluded, the pathogenetic link between the use of mitoxantrone and the development of secondary leukaemia was strongly supported in this case by the lack of concomitant potentially leukaemogenic treatments as well as by the morphologic and cytogenetic characteristics of leukaemia, the lack of myelodysplasia and the short latency period. Moreover, the evidence of early molecular relapse indicates a prognosis worse than that expected in APL patients treated with ATRA, a frequent characteristic of secondary neoplasms. We conclude that a note of caution may be suggested in the early use of this potentially dangerous agent in chronic nonmalignant diseases like MS.
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TO THE EDITOR
Extramedullary myeloid tumors (EMMT) are peculiar neoplasms that derive from myeloid progenitors, onset as solid masses in different tissues, involving bone marrow and peripheral blood only at the latest stages of progression. 1 The prognosis is strictly related to a correct diagnosis and a prompt intervention with a fitting treatment. In fact, patients are curable when treated early with conventional regimens for acute myeloid leukemias (AML); unfortunately, however, the initial diagnosis is frequently not correct and the appropriate treatment is delayed, with subsequent unsatisfactory results. Bone marrow transplantation (BMT) is probably the only curative approach in lately diagnosed cases, but it is rarely suitable for the high toxicity; new strategies are thus warranted in order to improve the outcome.
1,2
Increase of angiogenesis has been described in myeloproliferative disorders, such as AML and myelodysplastic syndromes (MDS), with clues to prognosis, [3] [4] [5] whereas no data are available in EMMT. Alpha-interferon (a-IFN) has been reported to be an antiangiogenic agent with clinical efficacy in a few cases of solid tumors. 6 In vitro data show that doses of IFN equivalent to thousand units in vivo are able to exert antiangiogenic activity, provided that a daily administration is effected. We thus studied the effects of an approach with microdoses of a-IFN in a young patient with EMMT refractory to salvage therapy after relapse, evaluating the effects produced on a surrogate angiogenesis marker.
In 1998, a 23-year-old man was diagnosed at another Institution for extranodal anaplastic large-cell lymphoma, localized at the ileopsoas muscle with involvement of the acetabulum and then treated with six courses of CHOP (cyclofosfamide 750 mg/m 2 i.v. day 1; doxorubicin 50 mg/m 2 i.v. day 1; vincristine 1.4 mg/m 2 i.v. day 1; prednisone 100 mg/m 2 p.o. days 1-5) and local radiotherapy (3000 cGy). After 18 months, he relapsed with a localization of disease to femora, tibia and ribs; he received three IEV courses (ifosfamide 2500 mg/m 2 i.v. days 1-3; etoposide 150 mg/m 2 i.v. days 1-3; epirubicine 100 mg/m 2 i.v. day 1) with the progression of disease during the treatment. PBSC were then collected in order to perform an autologous bone marrow transplant (ABMT). The patient was then evaluated at our Institute and the histological diagnosis was reviewed and reformulated as compatible with EMMT. The patient thus received an ABMT conditioned with busulfan 4 mg/kg p.o. days À3 to À6 and melphalan 140 mg/m 2 i.v. day À2, a conditioning regimen effective in AML. No therapy has been proposed for reinduction of complete remission before ABMT, because of the high previous toxicity; in particular, left ventricular ejection resulted was poor (the ejection fraction was 40%). Local radiotherapy (2100 cGy fields) was then applied after recovery from ABMT. Unfortunately, the restaging performed 1.5 months after the end of radiotherapy showed a progression of the disease.
We thus administered to the patient a-IFN, at low doses (10.000 IU s.c./day) daily for 6 months. The angiogenesis parameters were studied at baseline, before starting a-IFN treatment. MVD resulted significantly increased in comparison with normal tissue and plasmatic basic fibroblast growth factor (bFGF), a surrogate angiogenesis parameter, was again increased if compared with normal parameters (Figure 1) . The patient did not experience side effects during the treatment; his phisical conditions improved.
After the 6 months treatment period, a restaging was performed. Positron emission tomography (PET) and standard radiograms documented a good partial response, with disappearance of two out of three bone lesions.
Laboratory tests showed a concomitant clear reduction of plasmatic bFGF (Figure 1) . We then continued the treatment, for a further period of 3 months, when disease progressed. At this time, Received 26 December 2002; accepted 15 January 2003
